Boston Therapeutics, Inc. Announces Clinical Study Safety Results With SUGARDOWN(R) at University of Sydney  
1/24/2012 11:47:25 AM

MANCHESTER, N.H., Jan. 24, 2012 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (BTI), a developer of diabetes therapeutics, announced today the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN®, a dietary supplement designed to reduce post-meal elevation of blood glucose.